Navigation Links
Anti-malarial Drug may Help Reduce Risk of Diabetes in Rheumatoid Arthritis Patients

Preliminary research has suggested that use of the anti-malarial drug hydroxychloroquine may help reduce the risk of patients with rheumatoid arthritis developing diabetes .

Type 2 diabetes mellitus affects nearly 8 percent of US adults, and its prevalence has been increasing.

Antimalarials such as hydroxychloroquine, a long-standing safe and inexpensive treatment for an autoimmune disease such as rheumatoid arthritis, theoretically may improve glucose tolerance and prevent diabetes mellitus, according to background information in the article. In vitro and animal studies indicate that antimalarials improve insulin secretion and peripheral insulin sensitivity.

Mary Chester M. Wasko, M.D., M.Sc., of the University of Pittsburgh, Pa., and colleagues examined the association between hydroxychloroquine therapy and risk of diabetes in patients with rheumatoid arthritis.

During the observation period, incident diagnoses of diabetes were reported by 54 patients who had taken hydroxychloroquine and by 171 patients who had never taken it. Analysis indicated that patients who had taken hydroxychloroquine had a 38 percent lower risk of developing diabetes, compared with those who had not taken hydroxychloroquine. This risk was further reduced with increased duration of hydroxychloroquine use. Patients who took hydroxychloroquine for more than four years had a 77 percent lower risk of diabetes compared with those who had never taken hydroxychloroquine.

"We report herein the first evidence, to our knowledge, suggesting that use of hydroxychloroquine is associated with a reduced risk of developing diabetes in patients with rheumatoid arthritis. Moreover, risk reduction increased with duration of hydroxychloroquine exposure, supporting a biological action of this drug on glucose metabolism," the authors wrote.

The researchers also said that 'anti-malarial drugs may have a role in treating rheumato id arthritis not only to suppress synovitis [inflammation around the joints] but also to reduce the likelihood of developing glucose intolerance and dyslipidemia [abnormal concentrations of lipids'.

"While our study showed a reduction in diabetes incidence specifically in a rheumatoid arthritis cohort taking hydroxychloroquine, these findings also may be expected to occur in patients without rheumatoid arthritis. The beneficial changes in glucose metabolism and insulin sensitivity reported among patients with lupus, patients with type 2 diabetes, and in animal models suggest that these effects are not specific to rheumatoid arthritis."

"Anti-malarial drugs may have a role in treating rheumatoid arthritis not only to suppress synovitis [inflammation around the joints] but also to reduce the likelihood of developing glucose intolerance and dyslipidemia [abnormal concentrations of lipids]. As quality of life and life expectancy improve for patients with rheumatoid arthritis, and health care costs escalate, the use of inexpensive, safe therapies that have multiple beneficial effects is attractive.

Further prospective studies are needed to determine whether this treatment option should be considered a standard component of rheumatoid arthritis combination therapy in the future, and to evaluate the potential role of hydroxychloroquine as a preventive agent for diabetes among high-risk individuals in the general population," the researchers concluded.


'"/>




Related medicine news :

1. Cheap Anti-malarial Drug
2. Reduced POD linked to fatal asthma attacks
3. Reduced fertility in men who mountain bike
4. Reduce watching TV to prevent Obesity and Diabetes
5. Mammograms Reduce Risk of Dying
6. Night Time Aspirin Regimen Found to Reduce Blood Pressure
7. Reduced Fatigue Boosts Mental Health
8. Gynecological Surgeries Reduce Cancer Risk
9. Drug Reduces Risk of Clogged Arteries, Veins
10. Adding Fish to Diet May Reduce Risk of Alzheimers
11. Sunshine Reduces MS Risk
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/27/2017)... Cranbury, NJ (PRWEB) , ... March 27, 2017 ... ... publication of cutting-edge news, research and conference coverage on veterinary medicine, announces the ... The inaugural issue will be packaged with the April edition of American Veterinarian™. ...
(Date:3/27/2017)... Farmingdale, NY (PRWEB) , ... March 27, 2017 ... ... specializing in epigenetic research products enables researchers to pursue the recent RNA methylation ... RNA methylation . In light of the newfound characteristics of N6-methyladenosine, or ...
(Date:3/27/2017)... (PRWEB) , ... March 27, 2017 , ... According to ... prostate cancer, including all stages, is more than 95%. Once the cancer spreads to ... less than 30%. To find out how to avoid this latter group, tune in ...
(Date:3/27/2017)... ... March 27, 2017 , ... ?Grow Healthy Vending LLC announced ... litigation between itself and 1800 Vending DBA Healthy You Vending. (Civil No. 1:14-CV-00121-CW/ ... to announce that we have now reached a settlement agreement regarding the ongoing ...
(Date:3/27/2017)... ... March 27, 2017 , ... Harris Communications, Inc., a leading provider of ... latest products to the Deaf Seniors of America Conference, April 4-7 at the Hotel ... with knowledgeable ASL friendly staff from Harris Communications and to try out the newest ...
Breaking Medicine News(10 mins):
(Date:3/27/2017)... 27, 2017 FinancialBuzz.com News Commentary  ... Based on New Frontier Data,s ... where cannabis is legal will generate $655 million in taxes on ... cannabis specific taxes, such as Washington State,s ... earned from state sales taxes that are applied on all retail ...
(Date:3/27/2017)... March 27, 2017 BioLineRx Ltd. (NASDAQ/TASE: ... announced today that AGI-134, an immunotherapy for the treatment of ... Ltd., will be featured at the upcoming American Association ... Washington, DC to be held on April 1-5, ... ...
(Date:3/27/2017)... 2017   Pulmatrix, Inc . (NASDAQ: PULM), a clinical ... pulmonary diseases, today announced that it has added two experts ... asthma to its Scientific Advisory Board . ... B. Moss , MD, former chief of the Pediatric Pulmonary ... Center at Stanford University, and David ...
Breaking Medicine Technology: